InvestorsHub Logo

Millstone

11/09/15 12:15 PM

#33365 RE: Mikesc #33360

This quote from Dr. Missling in this morning's press release really stood out to me along with a number of other great quotes:

“While we remain focused on Alzheimer’s, the remarkably fast onset of clinical effect of ANAVEX 2-73 increases our options to potentially pursue additional indications for diseases characterized by working memory impairment and may enable clinical trials to be completed within shorter time frames.” [emphasis added]

Could this be hinting at a fast track designation for Parkinsons, Epilepsy, Alzheimers, or?

Millstone